Independent · evidence-based · non-judgmentalDraft · pending medical review
Not yet medically reviewed — information on this site is in preparation and has not been verified by a medical reviewer.
Drug index / Psychedelic / DMT
Psychedelic

DMT

2-(1H-indol-3-yl)-N,N-dimethylethanamine

DMT is a powerful, short-acting psychedelic (the key compound in ayahuasca); risks are mainly psychological, plus dangerous interactions when combined with MAOIs or other serotonergic drugs.

Overview

DMT (N,N-dimethyltryptamine) is a powerful, fast-acting psychedelic. When smoked or vaporized its effects come on within seconds and last only a short time — often described as an extremely intense, immersive experience. DMT is also the key psychoactive component of ayahuasca, a brewed preparation traditionally used in parts of South America, in which DMT is combined with a plant containing a monoamine oxidase inhibitor (MAOI) so that it becomes orally active and the experience lasts for hours. DMT is not associated with the compulsive, dependence-driven use of drugs like opioids or stimulants, and it rarely causes fatal poisoning on its own, but it produces profound changes in perception and thought, and the ayahuasca combination introduces specific and serious interaction risks.

Source: DEA; PubChem CID 6089

Chemistry & mechanism of action

Like other classic psychedelics, DMT acts mainly on the brain's serotonin system, binding to 5-HT2A receptors in regions involved in perception, mood, and cognition, which produces its characteristic alterations in sensory experience and sense of self. Smoked or injected, DMT is broken down very rapidly by the body's monoamine oxidase enzymes, which is why its effects are so brief. In ayahuasca, a plant-derived MAOI blocks that breakdown, allowing orally-taken DMT to reach the brain and produce a long experience — but blocking monoamine oxidase is also what creates ayahuasca's danger, because MAOIs interact seriously with many foods and medications. DMT does not produce physical dependence or withdrawal.

Source: PubChem CID 6089

Effects

Smoked or vaporized DMT produces a rapid, overwhelming psychedelic experience: intense visual imagery, a profound altered sense of reality and self, and strong emotional and sometimes 'mystical' content, typically over within a short period. Physical effects can include raised heart rate and blood pressure, dizziness, and nausea. Taken as ayahuasca, the onset is slower and the experience lasts for hours, and vomiting and diarrhea (purging) are common and often considered part of the traditional practice. As with all psychedelics, the experience can become frightening — intense fear, confusion, or panic — particularly at high doses or in an unsupportive setting, and impaired judgment during the experience can lead to accidents.

Source: DEA

Risks & harms

DMT's risks are primarily psychological — overwhelming fear, panic, or confusion during the experience, and a higher risk of lasting adverse psychiatric reactions in people with a personal or family history of psychosis or serious mental illness. The most important physical danger is specific to the ayahuasca combination: because it contains a monoamine oxidase inhibitor (MAOI), it can interact dangerously with many medications — including certain antidepressants (SSRIs, SNRIs, other MAOIs), some stimulants, and others — potentially causing serotonin syndrome or a hypertensive crisis, which can be life-threatening. Certain foods and pre-existing heart conditions add risk. Raised heart rate and blood pressure can also be hazardous for people with cardiovascular disease. There is no medication that reverses DMT; a difficult experience is managed with calm reassurance and a safe environment, and severe agitation, chest pain, very high temperature, or medical symptoms warrant emergency care. For poisoning guidance call Poison Control at 1-800-222-1222; for substance-use or mental-health support the SAMHSA National Helpline is 1-800-662-4357.

Source: DEA; SAMHSA

Subjective effects

intense visual hallucinations, depersonalization, auditory distortion, altered time/body image

Onset

very rapid

Duration

resolves 30–45 min

Harmful effects

hypertension, raised HR, agitation, seizures, dilated pupils, nystagmus, dizziness, ataxia; coma + respiratory arrest reported

Medicinal use

none in US

History

first synthesized by Richard Manske (British chemist) 1931; Schedule I since CSA 1971; used in ayahuasca (oral activity requires MAOI/harmala alkaloids)

Prevalence

NFLIS >11,800 reports since 1999 (~817 in 2024); all 50 states + DC + PR

Images

Visual references coming soon.

If it’s too intense

If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.

  • Get to a calm, safe space with someone you trust who is sober and can stay with you.
  • Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
  • Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
  • Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
  • A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
  • Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.

With psychedelics, fear and confusion are usually temporary. Change your surroundings — calmer light, quiet music, a trusted person — and remind yourself it will lift as the drug wears off.

Call 911 (or Poison Control, 1-800-222-1222) right away for chest pain, a very high body temperature, a seizure, unconsciousness, or severe confusion. These are medical emergencies, not something to wait out.

Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.

Forensic dossier

Draft · every field is source-cited or marked “Unknown — pending review”

Identity

IUPAC name
2-(1H-indol-3-yl)-N,N-dimethylethanaminePubChem PUG-REST · retrieved 2026-06-18
SMILES
CN(C)CCC1=CNC2=CC=CC=C21PubChem PUG-REST · retrieved 2026-06-18
InChIKey
DMULVCHRPCFFGV-UHFFFAOYSA-NPubChem PUG-REST · retrieved 2026-06-18
Synonyms / aliases
dimitri, the spirit molecule, N,N-DIMETHYLTRYPTAMINE, DIMETHYLTRYPTAMINE, 3-(2-Dimethylaminoethyl)indole, DEA No. 7435, N,N Dimethyltryptamine, A1AFV, DMT (psychogenic), (psychogenic), NN-Dimethyltryptamine, Dimethyltryptamine(DMT)PubChem PUG-REST + seed aliases · retrieved 2026-06-18

Composition

Composition
N/A — single compound (see Identity)

Physical / pill characteristics

Dosage form
HUMAN PRESCRIPTION DRUGopenFDA drug label · retrieved 2026-06-18
Route
INTRAMUSCULAR, INTRAVENOUSopenFDA drug label · retrieved 2026-06-18
Shape
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Color
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Imprint
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)
Score
Unknown — pending review (verify tablet imprint/shape against NLM Pillbox/DailyMed; N/A if not an oral tablet)

Scheduling & legal status

US schedule
Unknown — pending review
International
See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA · retrieved 2026-06-18

Effects

Effects
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Risks

Risks
Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus · retrieved 2026-06-18

Interactions

Interactions
See DailyMed label §Drug Interactions (Rx) — synthesize + cite per itemDailyMed SPL §Drug Interactions · retrieved 2026-06-18

Dosage

Pending medical reviewer

Sources

← Back to the drug index